Cellectis Earns 'Moderate Buy' Rating from Analysts

Biotech firm's stock price target set at $6.33 on average

Published on Feb. 18, 2026

Got story updates? Submit your updates here. ›

Cellectis S.A., a clinical-stage biopharmaceutical company specializing in gene-edited cell therapies for oncology, has earned a 'Moderate Buy' consensus rating from five brokerages covering the stock. The average 12-month price target on the stock is $6.33.

Why it matters

Cellectis is a pioneer in the development of allogeneic CAR-T cell therapies, an emerging field with significant potential to treat blood cancers and solid tumors. The 'Moderate Buy' rating and price target from analysts suggest cautious optimism about the company's prospects as it advances its pipeline of novel immunotherapies.

The details

One research analyst has rated Cellectis' stock with a 'sell' recommendation, while three have assigned 'buy' ratings and one has issued a 'strong buy'. Jefferies Financial Group recently assumed coverage on the stock with a 'buy' rating and $7 price target, while Wells Fargo & Company reissued a 'positive' rating with a $4 price target.

  • Cellectis' stock has traded between a 12-month low of $1.10 and a high of $5.48.

The players

Cellectis S.A.

A clinical-stage biopharmaceutical company specializing in the development of gene-edited cell therapies for oncology, founded in 1999 and headquartered in Paris, France, with additional operations in New York City and Raleigh, North Carolina.

Jefferies Financial Group

An investment banking firm that recently assumed coverage on Cellectis' stock with a 'buy' rating and $7 price target.

Wells Fargo & Company

A financial services company that has reissued a 'positive' rating on Cellectis' stock with a $4 price target.

Got photos? Submit your photos here. ›

What they’re saying

“We must not let individuals continue to damage private property in San Francisco.”

— Robert Jenkins, San Francisco resident (San Francisco Chronicle)

The takeaway

Cellectis' 'Moderate Buy' rating and average $6.33 price target from analysts suggest cautious optimism about the company's potential as it advances its pipeline of novel gene-edited cell therapies for cancer treatment, an emerging field with significant promise.